Tomorrow people
How CSOs can look to the future to forge successful relationships with pharma
PharmaTimes -
December 2018
They say all good things must come to an end, and I’m sad to say this will be my last issue at PharmaTimes – though I’m leaving the magazine in very capable hands with the existing PT team, including long-time news editor Selina, who will be taking over the editor role soon!
2018 has been one of the most interesting years I can remember since starting in the pharma industry, so it seems fitting for my final issue to take a look at the biggest stories of the past year with some of PT’s best writers.
This year the industry has faced some amazing advances that we could only have dreamed about a few years ago – from AI to 3D printed drugs and nanorobots – as well as some old stalwart issues like NHS challenges, controversial patent cases and big M&A deals. We analyse all of these starting on p16.
Elsewhere in the magazine we take a look at a potential new avenue to prevent the devastating graft versus host disease (p38) and ask some sales experts how pharma can best work with CSOs (p32).
I hope you’ve enjoyed the issues over the last couple of years, and will continue to enjoy them in the future (I’m certainly looking forward to becoming a PT reader!).
Digital edition sponsored by
December 2018 - magazine highlights
Patient Files: Cystic Fibrosis
Rachel Agutter’s parents were told she would only live till 12 – now 40, she talks to PharmaTimes about living with a disease where her luck could run out at any moment
SmartPeople: Tarek Sherif
We caught up with Medidata’s co-founder and CEO at the most recent NEXT conference to see how he expects digital R&D processes to transform the industry
Company focus: Kiadis
Amsterdam-based Kiadis has a unique approach to tackling the ‘terrifying’ graft versus host disease that can result from bone marrow transplants. We spoke to CEO Arthur Lahr to find out why this is such an important disease area to address
A record-breaking year for biotech funding
2018 has been a year where private rounds of funding have dominated headlines in the sector, and a record-breaking year for private investment in biotech
2018 – a slow year for M&A?
The value and volume of deals in H1 were higher than in the full year 2017, but a slow second half puts us a long way off 2015’s records
The age of personalised medicine is coming
James Huang & Stephen Huang on the groundbreaking technologies that could change precision medicine in the near future
2018 patent case highlights
The biggest cases of the past year
AI is not new
...But this year its impact, and the potential for change, was felt across the pharma industry
Biosimilars: recent legal and regulatory developments
The true impact of biosimilars is starting to be felt across the industry
Integrated care agenda stimulates seismic change in 2018
The NHS has been taking an increasingly joined-up approach to care during 2018, significantly altering how it works with pharma
The gut microbiome – the macro debate
This year pharma began to turn its eye towards the power of the microbiome
Difficult divorce
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
